Want to see INBX full AI Analyst Report?
Top Page
Inhibrx Biosciences Inc
(NASDAQ:INBX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$89.00
▼(-27.48% Downside)
Action:Reiterated
Date:09/29/26
INBX scores low primarily due to very weak financial performance (minimal revenue, large recurring losses, heavy cash burn, and negative equity), which dominates the risk profile. Technicals are also soft with negative momentum, only partially mitigated by oversold signals. Positive corporate events (strong Phase 2 data and expanded financing capacity) improve the outlook but are not enough to offset current financial strain and loss-making fundamentals.
Positive Factors
Phase 2 efficacy
The randomized Phase 2 results provide meaningful clinical validation for INBRX-106, with higher response and longer interim progression-free survival than monotherapy. These data support trial expansion and a potential Phase 3 path, improving the pipeline’s development and partnering prospects.
Negative Factors
No recurring revenue
The absence of meaningful recurring revenue leaves Inhibrx dependent on financing, collaborations, or future product success to support operations. Until a candidate is commercialized, the business has limited internal funding capacity and remains exposed to development timing and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 2 efficacy
The randomized Phase 2 results provide meaningful clinical validation for INBRX-106, with higher response and longer interim progression-free survival than monotherapy. These data support trial expansion and a potential Phase 3 path, improving the pipeline’s development and partnering prospects.
Read all positive factors
Inhibrx Biosciences Inc (INBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.33B
Dividend Yield5.23%
Average Volume (3M)304.31K
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue Growth-100.00%
EPS Growth19.23%
CountryUS
Employees110
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.88
Shares Outstanding14,717,660
10 Day Avg. Volume213,224
30 Day Avg. Volume304,311
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-910.83
Enterprise Value/Ebitda-12.73
Forecast
1Y Price Target
$266.67Price Target Upside117.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-9.41
Revenue Forecast (FY)N/A
Inhibrx Biosciences Inc Business Overview & Revenue Model
Company Description
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic ca...
How the Company Makes Money
Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company and does not have a stable, product-based commercial revenue stream typical of mature pharmaceutical companies. The company’s cash inflows generally come from (1) collaboration an...
Inhibrx Biosciences Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 1.30M | 200.00K | 1.80M | 2.19M | 7.13M |
| Gross Profit | -1.68M | -1.18M | -2.08M | 609.00K | -107.99M | 4.44M |
| EBITDA | -120.45M | -125.37M | 1.70B | -206.69M | -125.82M | -75.36M |
| Net Income | -138.18M | -140.06M | 1.69B | -241.36M | -145.23M | -81.77M |
Balance Sheet | ||||||
| Total Assets | 154.22M | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M |
| Cash, Cash Equivalents and Short-Term Investments | 133.34M | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M |
| Total Debt | 5.34M | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M |
| Total Liabilities | 207.20M | 138.49M | 47.18M | 264.39M | 232.82M | 98.07M |
| Stockholders Equity | -52.98M | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M |
Cash Flow | ||||||
| Free Cash Flow | -131.87M | -129.82M | -197.01M | -197.90M | -115.99M | -81.19M |
| Operating Cash Flow | -131.89M | -129.79M | -194.41M | -193.31M | -115.30M | -80.32M |
| Investing Cash Flow | 20.00K | -28.00K | -2.60M | -4.59M | -686.00K | -809.00K |
| Financing Cash Flow | 78.67M | 101.45M | 71.68M | 201.96M | 258.55M | 83.77M |
Inhibrx Biosciences Inc Technical Analysis
Negative
122.72
Price Trends
103.38
Negative
98.34
Negative
91.36
Negative
Market Momentum
-3.96
Positive
34.91
Neutral
15.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Negative. The current price of 122.72 is above the 20-day moving average (MA) of 100.28, above the 50-day MA of 103.38, and above the 200-day MA of 91.36, indicating a bearish trend. The MACD of -3.96 indicates Positive momentum. The RSI at 34.91 is Neutral, neither overbought nor oversold. The STOCH value of 15.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBX.
Inhibrx Biosciences Inc Risk Analysis
Inhibrx Biosciences Inc disclosed 89 risk factors in its most recent earnings report. Inhibrx Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibrx Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $4.09B | -23.40 | -17.49% | ― | 101.28% | 2.49% | |
57 Neutral | $1.86B | -11.54 | -28.66% | ― | -28.56% | 10.25% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $1.81B | -12.54 | -72.07% | ― | -69.78% | -106.07% | |
49 Neutral | $1.50B | -161.06 | -2.35% | ― | 20.19% | ― | |
48 Neutral | $1.08B | -4.06 | -47.04% | ― | -65.40% | -164.71% | |
46 Neutral | $1.33B | -10.19 | 1893.60% | 5.23% | -100.00% | 19.23% |
* General Sector Average
INBX
Inhibrx Biosciences Inc
90.53
55.72
160.07%
XNCR
Xencor
25.04
12.61
101.45%
ZYME
Zymeworks
25.33
7.10
38.95%
IMTX
Immatics
7.21
-2.96
-29.11%
ABCL
AbCellera Biologics
12.64
7.02
124.82%
IMCR
Immunocore Holdings
29.04
-2.68
-8.45%
Inhibrx Biosciences Inc Corporate Events
Business Operations and StrategyFinancial Disclosures
Inhibrx Biosciences Updates Investor Presentation and Pipeline Outlook
Positive
Sep 28, 2026
On September 28, 2026, Inhibrx Biosciences posted an updated corporate investor presentation outlining its pipeline progress, financial position and strategic milestones, including $219.5 million in cash and cash equivalents and 14.7 million commo...
Business Operations and StrategyProduct-Related Announcements
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data
Positive
Sep 8, 2026
On September 8, 2026, Inhibrx Biosciences reported primary endpoint data from the randomized Phase 2 HexAgon trial of INBRX-106 plus pembrolizumab versus pembrolizumab alone in first-line PD-L1–positive metastatic or unresectable recurrent h...
Business Operations and StrategyPrivate Placements and Financing
Inhibrx Biosciences Expands Credit Facility to $500 Million
Positive
Jul 17, 2026
On July 15, 2026, Inhibrx Biosciences Inc. amended its Loan and Security Agreement with Oxford Finance, expanding its credit facility to as much as $500 million and adding a new $325 million tranche. The company received an immediate $100 million ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.